12 results about "Dermatitis eczema" patented technology

The present invention relates generally to maqui berry for use in the treatment or prevention of skin diseases, wherein maqui berry may be the primary natural active ingredient. Particular embodiments as disclosed herein find application in, inter alia, the prophylaxis and the treatment of skin diseases, in particular, dermatitis, atopic dermatitis (neurodermatitis), dermatitis solaris, eczema, hand eczema, lichen planus, lupus erythematosus, psoriasis, urticaria, itching, scabies, age spot, freckles and dry / atopic skin of humans. In particular, the present invention relates to the use of maqui berry extract in the manufacture of a medicament or dietary supplement for use in treating or preventing said skin diseases or defects.

The invention relates to the technical field of skin medicines, in particular to a pharmaceutical composition for preventing or treating inflammatory skin diseases and application. The invention discloses a pharmaceutical composition for preventing or treating inflammatory skin diseases and application. The composition comprises active ingredients of astacin and derivatives thereof, p-toluene sulfonamide and derivatives thereof, and pharmaceutically or cosmetically acceptable excipients. Through the synergistic effect of the two active components, the composition can effectively inhibit skin inflammatory response, relieve pruritus and erythema and promote skin barrier repair and wound healing. The composition can be prepared into multiple external dosage forms such as cream, gel and spray, is suitable for preventing or treating multiple inflammatory skin diseases such as atopic dermatitis, eczema and psoriasis, and can also be used for repairing and nursing skin wounds. The external formula provided by the invention has both curative effect and safety, and provides a new choice for the treatment of inflammatory dermatosis.

The application discloses application of a human lactoferricin peptide in anti-inflammatory soothing and skin barrier repair. The application relates to the field of biotechnology, and provides application of a polypeptide or a biological material related to the polypeptide in preparation of a product with anti-inflammatory soothing and / or skin barrier repair functions; the polypeptide is a human lactoferricin peptide derived from a filtrate of a yeast fermentation lysate product, and an amino acid sequence of the polypeptide is shown as SEQ ID NO:1. The polypeptide has intervention potential on inflammation related to dermatitis and eczema, especially on atopic dermatitis. The polypeptide can be applied to the fields of medicines and cosmetics.

Provided herein are compositions and their use for the treatment of human skin, particularly facial skin, to alleviate the symptoms of cosmetic or dermatologic skin conditions. The compositions include black willow bark extract, cat's claw extract, and dragon's blood extract. The compositions ameliorate skin conditions including acne, rosacea, blemish, dermatitis, eczema, or the like.

The invention discloses an anemoside B4 derivative as well as a preparation method and application thereof, a compound anemoside B4 (abbreviated as B4 or AB4) is taken as a raw material, and the derivative is prepared by respectively carrying out nucleophilic substitution, electrophilic addition, esterification reaction or amidation and other reactions on C-19 exocyclic double bonds or C-28 carboxyl. The compound is used as an active component to prepare medicines with anti-inflammatory and immunoregulation effects. The invention discloses the effect of the B4 derivative on treating inflammatory diseases such as inflammatory bowel disease, atopic dermatitis, eczema and psoriasis for the first time, and the drug effect of the B4 derivative is superior to that of B4 or clinically common drugs. In addition, the invention also discloses that most B4 derivatives do not show obvious cytotoxicity to macrophages for the first time, can reduce the P-I kappa Ba protein level in LPS and ATP induced macrophage NF-kappa B signaling pathways, inhibit the activation of NLRP3 signaling pathways and obviously reduce the Pro-IL-1beta level (p is less than 0.05), namely inhibit the activation of inflammasome pathways, and the effect is superior to that of B4; the results show that the B4 derivative disclosed by the invention has better anti-inflammatory activity.

The invention provides a recombinant collagen patch for treating facial dermatitis and eczema and fading pigmentation and a preparation method of the recombinant collagen patch. The application comprises a base material layer and a functional composition loaded on the base material layer, wherein the functional composition comprises recombinant human collagen III, an anti-inflammatory active component and a whitening active component. Wherein the anti-inflammatory active component is a compound of ganoderma sinensis spore powder zymolyte, dipotassium glycyrrhizinate and asiaticoside in a specific mass ratio, and the whitening active component is an alpha-arbutin-ferulic acid condensate and a compound of tranexamic acid and glabridin in a specific mass ratio. And the base material layer is alginate-sodium carboxymethyl cellulose composite hydrogel which is modified by gamma-ray irradiation. Through the synergistic effect of all the active ingredients and the optimized preparation process, the multiple effects of resisting inflammation, repairing a barrier and fading hyperpigmentation are achieved, and the product is good in biocompatibility and remarkable in effect.

A method for manufacturing medicinal fabric that provides enhanced dermatological comfort for the user / patient, especially those with sensitive skin conditions (e.g., acne, contact dermatitis, atopic dermatitis, eczema, psoriasis, rosacea, urticaria, etcetera) including the steps of: (1) selecting a cotton fiber, wherein the cotton fiber is long staple cotton and 100 percent organic; (2) processing the cotton fiber as greige cotton; (3) optionally verifying that the cotton fiber is organic per Global Organic Textile Standards or comparable standards; (4) fermenting or otherwise naturally preparing an herb or plant into a medicinally potent agent / substance and hypoallergenic dyeing agent; (5) using a skin-friendly binding technique, such as binderless dyeing the cotton fiber with the agent / substance via ultrasonic energy or using a technique that similarly uses no irritative chemical binders; (6) selecting a suitable weave type for the specific use / case to reduce mechanical irritation to the user / patient; (7) optionally verifying that the woven cotton fiber has not been contaminated during the manufacturing process through toxicological verification methods; and (8) optionally verifying that the woven cotton fiber passes the standardized dermatological Human Repeat Insult Patch Test.

The present application belongs to the technical field of biological medicine, and particularly relates to a composition for treating atopic dermatitis and application thereof. The mass ratio of each component of the composition is: notoginseng extract: artemether: wujin glycoside: oleanolic acid = (2-4):(2-4):(1-2):(1-2). The composition has the effects of anti-inflammation and anti-itching, and can treat atopic dermatitis, eczema and other diseases. The active ingredients of the composition are all of plant origin, have good safety and the treatment effect on atopic dermatitis, and have a low dosage. The components can achieve a synergistic effect, and show excellent effects. The composition can be applied to functional skin care products (cream, emulsion, essence) and external drugs (ointment).

The invention discloses an application of betulinic acid 28-O-beta-D-glucoside (BA-6 for short) in preparation of a medicine for preventing and treating skin inflammation. The problems that an existing medicine for treating dermatitis is limited in curative effect, slow in effect taking, multiple in side effect, high in long-term use risk, large in individual difference, high in treatment cost, likely to cause immunoreaction and the like are solved. The invention discloses application of BA-6 in prevention and treatment of atopic dermatitis, contact dermatitis, eczema, rash, psoriasis, lupus erythematosus, papule squamous skin disease, pityriasis rosea, seborrheic dermatitis, pemphigus, celestial abscess, acne, tinea corporis, impetigo, SAPHO syndrome, hidradenitis suppurativa, dermatitis caused by drugs, lichen planus, pityriasis rubra pilaris, vitiligo, prurigo nodularis, dermatitis caused by drugs, and the like for the first time. The traditional Chinese medicine composition can be used for treating skin diseases, systemic sclerosis, hidradenitis suppurativa, granulomatous skin diseases, vitiligo, dermatomyositis, chronic skin itch and alopecia areata, and has the technical progress of obviously improving skin erythema, papule, edema, scale, moss and ulceration symptoms.

This invention belongs to the field of medical materials technology and discloses a medical composite dressing for relieving dermatitis and eczema and its preparation method. First, mussel adhesive protein is dissolved in purified water, and the pH is adjusted to obtain a mussel adhesive protein solution. Trehalose, ectoine, and a portion of glycerin are mixed and dissolved to obtain an active ingredient composite solution. Then, the mussel adhesive protein solution and the active ingredient composite solution are mixed, and the pH is adjusted to obtain phase A. Sodium carboxymethyl cellulose is dissolved in a buffer solution in batches to obtain sodium carboxymethyl cellulose solution A and sodium carboxymethyl cellulose solution B. The two solutions are mixed, and the remaining glycerin and methylparaben are added. After adjusting the pH, phase B is obtained. Finally, phase A is added dropwise to phase B, stirred, and allowed to stand for maturation to obtain the final product. The medical composite dressing provided by this invention has a unique temperature-pH response mechanism, enabling the release of active ingredients such as ectoine and trehalose under weakly acidic conditions, achieving targeted repair and moisturizing of the inflamed area.

The invention belongs to the field of preparation of specific medicinal liquor, and particularly relates to specific medicinal liquor for treating pain, itching, hot and cough toxin diseases and a preparation method of the specific medicinal liquor. The preparation method comprises the following steps: grinding multifunctional mixed Chinese herbal medicines into powder, soaking Chinese herbal medicine powder with litsea cubeba oil and a calcium ion solution, and rapidly and fully crushing cell walls and cell membranes of Chinese herbal medicine plants with increased brittleness in cooperation with an ultrasonic crusher to release all effective components; the yellow wine can accelerate blood circulation, high-concentration alcohol rapidly penetrates through the medicinal materials under the action of magnetic force, the solubility is enhanced, components released from Chinese herbal medicine cells are fully dissolved, and small molecule peptides obtained by taro protein decomposed by papain are matched, so that the medicinal liquor does not deteriorate while containing a large number of effective components and being high in medicine effect, and the medicinal liquor has a good health care effect. The symptoms of dermatitis-eczema mice with pain, pruritus, hot skin and toxin-containing skin are effectively relieved, and the cough inhibition rate reaches 34.9%.

Disclosed are compositions and their use for the treatment of human skin, particularly facial skin, to alleviate the symptoms of cosmetic or dermatologic skin conditions. The compositions include black willow bark extract, cats claw extract, and dragon's blood extract. The compositions ameliorate skin conditions including acne, rosacea, blemish, dermatitis, eczema, or the like.